{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:32Z","timestamp":1756902152385,"version":"3.44.0"},"reference-count":20,"publisher":"The Pediatric Pharmacy Association","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Although it was originally developed and approved for the treatment of various psychiatric conditions, such as schizophrenia and bipolar I disorder, recent studies have identified the role of olanzapine in the treatment of intensive care unit (ICU)\u2013related delirium and nausea and vomiting. Unfortunately, olanzapine is currently only indicated to be administered via the intramuscular (IM) route or enteral route, limiting the opportunity of its use in certain pediatric patients. IM injections are typically avoided in pediatrics whenever possible, and it is not uncommon for pediatric patients, especially those in an ICU setting, to be restricted to nothing by mouth. Studies in the adult population have demonstrated both safety and efficacy for the administration of reconstituted olanzapine powder by the intravenous (IV) route, which would provide an ideal administration route for pediatric patients unable to receive IM or enteral administration. We report a case series of 4 pediatric patients who received at least 1 dose of IV olanzapine. All 4 patients reported a positive response from the medication and no safety concerns were noted.<\/jats:p>","DOI":"10.5863\/1551-6776-28.8.752","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T19:08:07Z","timestamp":1702408087000},"page":"752-756","source":"Crossref","is-referenced-by-count":0,"title":["Avoiding a Poke: A Case Series of Intravenous Olanzapine in Pediatric Patients"],"prefix":"10.5863","volume":"28","author":[{"given":"Abdiweli","family":"Hassan","sequence":"first","affiliation":[{"name":"College of Pharmacy (AH), Midwestern University, Glendale, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Raschka","sequence":"additional","affiliation":[{"name":"Pharmacy Department (MR), Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"year":"2022","key":"i2331-348X-28-8-752-b01","unstructured":"Olanzapine [package insert]. Mumbai, India: Alkem Laboratories Ltd.; 2022."},{"issue":"(8)","key":"i2331-348X-28-8-752-b02","series-title":"Ann Pharmacother","first-page":"853","article-title":"Intravenous olanzapine for the management of agitation: review of the literature","volume":"53","author":"Khorassani","year":"2019","unstructured":"Khorassani\n              F\n            , SaadM. Intravenous olanzapine for the management of agitation: review of the literature. Ann Pharmacother. 2019;53(8):853\u2013859."},{"year":"2020","key":"i2331-348X-28-8-752-b03","unstructured":"Olanzapine [package insert]. Andhra Pradesh, India: Gland Pharma Ltd.; 2020."},{"issue":"(2)","key":"i2331-348X-28-8-752-b04","series-title":"N Engl J Med","first-page":"134","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","unstructured":"Navari\n              RM\n            , QinR, RuddyKJ, \n          . Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134\u2013142."},{"issue":"(2)","key":"i2331-348X-28-8-752-b05","series-title":"Pediatr Emerg Care","first-page":"70","article-title":"The use, safety, and efficacy of olanzapine in a level I pediatric trauma center emergency department over a 10-year period","volume":"36","author":"Cole","year":"2020","unstructured":"Cole\n              JB\n            , KleinLR, StrobelAM, \n          . The use, safety, and efficacy of olanzapine in a level I pediatric trauma center emergency department over a 10-year period. Pediatr Emerg Care. 2020;36(2):70\u201376."},{"issue":"(6)","key":"i2331-348X-28-8-752-b06","series-title":"Hosp Pharm","first-page":"697","article-title":"Off-label use of intravenous olanzapine for agitation after neurologic injury","volume":"56","author":"Tsai","year":"2021","unstructured":"Tsai\n              YV\n            , FawzyJH, DurkinJB, \n          . Off-label use of intravenous olanzapine for agitation after neurologic injury. Hosp Pharm. 2021;56(6):697\u2013701."},{"issue":"(2)","key":"i2331-348X-28-8-752-b07","series-title":"Hosp Pharm","first-page":"108","article-title":"Intravenous olanzapine in a critically ill patient: an evolving route of administration","volume":"55","author":"Lorenzo","year":"2020","unstructured":"Lorenzo\n              MP\n            , BurgessJ, DarkoW. Intravenous olanzapine in a critically ill patient: an evolving route of administration. Hosp Pharm. 2020;55(2):108\u2013111."},{"issue":"(9)","key":"i2331-348X-28-8-752-b08","series-title":"Ann Pharmacother","first-page":"1127","article-title":"Safety of intravenous olanzapine administration at a tertiary academic medical center","volume":"55","author":"Hunt","year":"2021","unstructured":"Hunt\n              NF\n            , McLaughlinKC, KovacevicMP, \n          . Safety of intravenous olanzapine administration at a tertiary academic medical center. Ann Pharmacother. 2021;55(9):1127\u20131133."},{"issue":"(1)","key":"i2331-348X-28-8-752-b09","series-title":"Acad Emerg Med","first-page":"29","article-title":"A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department","volume":"23","author":"Martel","year":"2016","unstructured":"Martel\n              ML\n            , KleinLR, RivardRL, ColeJB. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Acad Emerg Med. 2016;23(1):29\u201335."},{"issue":"(3)","key":"i2331-348X-28-8-752-b10","series-title":"Ann Emerg Med","first-page":"327","article-title":"A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department","volume":"69","author":"Cole","year":"2017","unstructured":"Cole\n              JB\n            , MooreJC, DolanBJ, \n          . A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. Ann Emerg Med. 2017;69(3):327\u2013336.e2."},{"issue":"(6)","key":"i2331-348X-28-8-752-b11","series-title":"Australas Psychiatry","first-page":"604","article-title":"Management of a complex patient\u2013intravenous olanzapine use","volume":"26","author":"Goh","year":"2018","unstructured":"Goh\n              PY\n            , HuangB, PehlivanN. Management of a complex patient\u2013intravenous olanzapine use. Australas Psychiatry. 2018;26(6):604\u2013607."},{"issue":"(2)","key":"i2331-348X-28-8-752-b12","series-title":"J Int Care Med","first-page":"222","article-title":"A retrospective comparison of the effectiveness and safety of intravenous olanzapine versus intravenous haloperidol for agitation in adult intensive care unit patients","volume":"37","author":"Wang","year":"2022","unstructured":"Wang\n              M\n            , YankamaTT, AbdallahGT, \n          . A retrospective comparison of the effectiveness and safety of intravenous olanzapine versus intravenous haloperidol for agitation in adult intensive care unit patients. J Int Care Med. 2022;37(2):222\u2013230."},{"issue":"(2)","key":"i2331-348X-28-8-752-b13","series-title":"J Pediatr Intensive Care","first-page":"49","article-title":"Olanzapine reduces delirium symptoms in the critically ill pediatric patient","volume":"2","author":"Sassano-Higgins","year":"2013","unstructured":"Sassano-Higgins\n              S\n            , FreudenbergN, JacobsonJ, TurkelS. Olanzapine reduces delirium symptoms in the critically ill pediatric patient. J Pediatr Intensive Care. 2013;2(2):49\u201354."},{"issue":"(2)","key":"i2331-348X-28-8-752-b14","series-title":"J Pediatr Intensive Care","first-page":"119","article-title":"Management of hyperactive delirium in the pediatric intensive care unit: case series of three young children","volume":"9","author":"Jesus","year":"2020","unstructured":"Jesus\n              AO\n            , JonesL, LinaresR, \n          . Management of hyperactive delirium in the pediatric intensive care unit: case series of three young children. J Pediatr Intensive Care. 2020;9(2):119\u2013123."},{"issue":"(2)","key":"i2331-348X-28-8-752-b15","series-title":"J Child Adolesc Psychopharmacol","first-page":"126","article-title":"Atypical antipsychotic medications to control symptoms of delirium in children and adolescents","volume":"22","author":"Turkel","year":"2012","unstructured":"Turkel\n              SB\n            , JacobsonJ, MunzigE, Tavar\u00e9CJ. Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. J Child Adolesc Psychopharmacol. 2012;22(2):126\u2013130."},{"issue":"(8)","key":"i2331-348X-28-8-752-b16","series-title":"J Pediatr Hematol Oncol","first-page":"446","article-title":"Efficacy and safety of olanzapine in children receiving highly emetogenic chemotherapy: a randomized, double-blind placebo-controlled phase 3 trial","volume":"44","author":"Moothedath","year":"2022","unstructured":"Moothedath\n              AW\n            , MeenaJP, GuptaAK, \n          . Efficacy and safety of olanzapine in children receiving highly emetogenic chemotherapy: a randomized, double-blind placebo-controlled phase 3 trial. J Pediatr Hematol Oncol. 2022;44(8):446\u2013453."},{"issue":"(32)","key":"i2331-348X-28-8-752-b17","series-title":"J Clin Oncol","first-page":"3785","article-title":"Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial","volume":"38","author":"Naik","year":"2020","unstructured":"Naik\n              RD\n            , SreenivasV, SinghV, \n          . Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. J Clin Oncol. 2020;38(32):3785\u20133793."},{"issue":"(3)","key":"i2331-348X-28-8-752-b18","series-title":"Pediatr Blood Cancer","first-page":"496","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review","volume":"62","author":"Flank","year":"2015","unstructured":"Flank\n              J\n            , ThackrayJ, NielsonD, \n          . Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. Pediatr Blood Cancer. 2015;62(3):496\u2013501."},{"year":"2023","series-title":"Lexicomp","key":"i2331-348X-28-8-752-b19","unstructured":"Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Waltham, MA: UpToDate Inc.; 2023. Lexicomp. Accessed February 19, 2023, http:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/pdh_f\/128998?cesid=6GWyA55OOGS&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dolanzapine%26t%3Dname%26acs%3Dfalse%26acq%3Dolanzapine"},{"issue":"(9)","key":"i2331-348X-28-8-752-b20","series-title":"Mayo Clin Proc","first-page":"1225","article-title":"Frequency and appropriateness of fasting orders in the hospital","volume":"90","author":"Sorita","year":"2015","unstructured":"Sorita\n              A\n            , ThongprayoonC, AhmedA, \n          . Frequency and appropriateness of fasting orders in the hospital. Mayo Clin Proc. 2015;90(9):1225\u20131232."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/8\/article-p752.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/8\/752\/3299331\/i2331-348x-28-8-752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/8\/article-p752.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/8\/article-p752.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:49:47Z","timestamp":1747356587000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/8\/article-p752.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":20,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.8.752","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2023]]}}}